| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adding to the mantra: vaccines prevent illness and death, and preserve existing antibiotics
|
Heymann, David L
|
|
|
22 |
8 |
p. 1108-1109
|
artikel
|
| 2 |
Alcoholic chlorhexidine skin preparation or triclosan-coated sutures to reduce surgical site infection: a systematic review and meta-analysis of high-quality randomised controlled trials
|
|
|
|
22 |
8 |
p. 1242-1251
|
artikel
|
| 3 |
ASM Microbe 2022
|
Mushtaq, Ammara
|
|
|
22 |
8 |
p. 1120
|
artikel
|
| 4 |
Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5
|
Arora, Prerna
|
|
|
22 |
8 |
p. 1117-1118
|
artikel
|
| 5 |
Availability of oral antivirals against SARS-CoV-2 infection and the requirement for an ethical prescribing approach
|
Dal-Ré, Rafael
|
|
|
22 |
8 |
p. e231-e238
|
artikel
|
| 6 |
Changes to treatment of drug-resistant tuberculosis
|
Venkatesan, Priya
|
|
|
22 |
8 |
p. 1123
|
artikel
|
| 7 |
Clinical features and management of human monkeypox: a retrospective observational study in the UK
|
Adler, Hugh
|
|
|
22 |
8 |
p. 1153-1162
|
artikel
|
| 8 |
Clinical sequelae among individuals with pauci-symptomatic or asymptomatic Ebola virus infection and unrecognised Ebola virus disease in Liberia: a longitudinal cohort study
|
Kelly, J Daniel
|
|
|
22 |
8 |
p. 1163-1171
|
artikel
|
| 9 |
Correction to Lancet Infect Dis 2021; 21: 1257–70
|
|
|
|
22 |
8 |
p. e207
|
artikel
|
| 10 |
Correction to Lancet Infect Dis 2022; published online June 21. https://doi.org/10.1016/S1473-3099(22)00234-1
|
|
|
|
22 |
8 |
p. e207
|
artikel
|
| 11 |
Correction to Lancet Infect Dis 2022; published online May 26. https://doi.org/10.1016/S1473-3099(22)00133-5
|
|
|
|
22 |
8 |
p. e207
|
artikel
|
| 12 |
Destroyed left lung due to multidrug-resistant Mycobacterium tuberculosis
|
Eskandari, Siawosh K
|
|
|
22 |
8 |
p. 1252
|
artikel
|
| 13 |
Doxycycline: the universal treatment for anogenital chlamydia
|
Fairley, Christopher K
|
|
|
22 |
8 |
p. 1102-1103
|
artikel
|
| 14 |
Doxycycline versus azithromycin for the treatment of anorectal Chlamydia trachomatis infection in women concurrent with vaginal infection (CHLAZIDOXY study): a multicentre, open-label, randomised, controlled, superiority trial
|
Peuchant, Olivia
|
|
|
22 |
8 |
p. 1221-1230
|
artikel
|
| 15 |
Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant
|
Higdon, Melissa M
|
|
|
22 |
8 |
p. 1114-1116
|
artikel
|
| 16 |
Estimating the global burden of sexually transmitted infections
|
Peters, Remco P H
|
|
|
22 |
8 |
p. 1112-1113
|
artikel
|
| 17 |
Estimating the global burden of sexually transmitted infections – Authors' reply
|
Zheng, Yang
|
|
|
22 |
8 |
p. 1113-1114
|
artikel
|
| 18 |
Experts react to SAGO's preliminary report
|
Samarasekera, Udani
|
|
|
22 |
8 |
p. 1121
|
artikel
|
| 19 |
Francine Ntoumi—building research capacity and encouraging female African researchers
|
Kirby, Tony
|
|
|
22 |
8 |
p. 1128
|
artikel
|
| 20 |
Guidelines for visceral leishmaniasis and HIV co-infection
|
Burki, Talha
|
|
|
22 |
8 |
p. 1124-1125
|
artikel
|
| 21 |
Halidou Tinto—leading top-quality research in malaria in Burkina Faso
|
Samarasekera, Udani
|
|
|
22 |
8 |
p. 1129
|
artikel
|
| 22 |
Heterologous booster response after inactivated virus BBIBP-CorV vaccination in older people
|
Rouco, Santiago Oviedo
|
|
|
22 |
8 |
p. 1118-1119
|
artikel
|
| 23 |
Immunoglobulin-free strategy to prevent HBV mother-to-child transmission in Cambodia (TA-PROHM): a single-arm, multicentre, phase 4 trial
|
Segeral, Olivier
|
|
|
22 |
8 |
p. 1181-1190
|
artikel
|
| 24 |
Infectious diseases compensation in the USA: the relative value
|
El Helou, Guy
|
|
|
22 |
8 |
p. 1106-1108
|
artikel
|
| 25 |
Infectious disease surveillance update
|
Zwizwai, Ruth
|
|
|
22 |
8 |
p. 1125
|
artikel
|
| 26 |
Mass drug administration of ivermectin, diethylcarbamazine, plus albendazole compared with diethylcarbamazine plus albendazole for reduction of lymphatic filariasis endemicity in Papua New Guinea: a cluster-randomised trial
|
Laman, Moses
|
|
|
22 |
8 |
p. 1200-1209
|
artikel
|
| 27 |
Omicron subvariants escape antibodies elicited by vaccination and BA.2.2 infection
|
Yao, Lin
|
|
|
22 |
8 |
p. 1116-1117
|
artikel
|
| 28 |
Pandemic diaries under the lens
|
Balakrishnan, Vijay Shankar
|
|
|
22 |
8 |
p. 1130
|
artikel
|
| 29 |
Phase 1 success for a trivalent vaccine for the equine encephalitis viruses
|
Suhrbier, Andreas
|
|
|
22 |
8 |
p. 1100-1102
|
artikel
|
| 30 |
Potential of triple-drug therapy to accelerate lymphatic filariasis elimination
|
Kelly-Hope, Louise
|
|
|
22 |
8 |
p. 1099-1100
|
artikel
|
| 31 |
Prevalence, incidence, and reported global distribution of noma: a systematic literature review
|
Galli, Anaïs
|
|
|
22 |
8 |
p. e221-e230
|
artikel
|
| 32 |
Prevalence of bacteriologically confirmed pulmonary tuberculosis in South Africa, 2017–19: a multistage, cluster-based, cross-sectional survey
|
Moyo, Sizulu
|
|
|
22 |
8 |
p. 1172-1180
|
artikel
|
| 33 |
Preventing mother-to-child transmission of HBV
|
Lu, Qing-Bin
|
|
|
22 |
8 |
p. 1096-1097
|
artikel
|
| 34 |
Reaching the vulnerable without stigma
|
The Lancet Infectious Diseases,
|
|
|
22 |
8 |
p. 1091
|
artikel
|
| 35 |
Real-world trends in incidence of bacterial sexually transmissible infections among gay and bisexual men using HIV pre-exposure prophylaxis (PrEP) in Australia following nationwide PrEP implementation: an analysis of sentinel surveillance data
|
Traeger, Michael W
|
|
|
22 |
8 |
p. 1231-1241
|
artikel
|
| 36 |
Research in brief
|
Devi, Sharmila
|
|
|
22 |
8 |
p. 1126
|
artikel
|
| 37 |
Risk of arterial and venous thromboses after COVID-19
|
Whiteley, William
|
|
|
22 |
8 |
p. 1093-1094
|
artikel
|
| 38 |
Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review
|
Uyttebroek, Saartje
|
|
|
22 |
8 |
p. e208-e220
|
artikel
|
| 39 |
Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial
|
Coates, Emily E
|
|
|
22 |
8 |
p. 1210-1220
|
artikel
|
| 40 |
Safety and immunogenicity of the Rotavac and Rotasiil rotavirus vaccines administered in an interchangeable dosing schedule among healthy Indian infants: a multicentre, open-label, randomised, controlled, phase 4, non-inferiority trial
|
Kanungo, Suman
|
|
|
22 |
8 |
p. 1191-1199
|
artikel
|
| 41 |
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial
|
Munro, Alasdair P S
|
|
|
22 |
8 |
p. 1131-1141
|
artikel
|
| 42 |
Sexually transmissible infection incidence in men who have sex with men using HIV pre-exposure prophylaxis in Australia
|
Cannon, Chase
|
|
|
22 |
8 |
p. 1103-1105
|
artikel
|
| 43 |
Statistical concerns for meta-analysis of rare events and small sample sizes
|
Zhou, Qi
|
|
|
22 |
8 |
p. 1111
|
artikel
|
| 44 |
Statistical concerns for meta-analysis of rare events and small sample sizes
|
Zhou, Shouhao
|
|
|
22 |
8 |
p. 1111-1112
|
artikel
|
| 45 |
Statistical concerns for meta-analysis of rare events and small sample sizes – Authors' reply
|
Sherwood, Emma
|
|
|
22 |
8 |
p. 1112
|
artikel
|
| 46 |
Stephen Blount
|
Bagcchi, Sanjeet
|
|
|
22 |
8 |
p. 1127
|
artikel
|
| 47 |
The first reactive vaccination campaign against hepatitis E
|
Ciglenecki, Iza
|
|
|
22 |
8 |
p. 1110-1111
|
artikel
|
| 48 |
The state of tuberculosis in South Africa: what does the first national tuberculosis prevalence survey teach us?
|
Ayles, Helen
|
|
|
22 |
8 |
p. 1094-1096
|
artikel
|
| 49 |
Time for noma to enter the global health stage
|
Benzian, Habib
|
|
|
22 |
8 |
p. 1105-1106
|
artikel
|
| 50 |
Vaccine pragmatism in the 21st century
|
Keddy, Karen H
|
|
|
22 |
8 |
p. 1097-1098
|
artikel
|
| 51 |
Venous or arterial thrombosis and deaths among COVID-19 cases: a European network cohort study
|
Burn, Edward
|
|
|
22 |
8 |
p. 1142-1152
|
artikel
|
| 52 |
What a second booster dose of mRNA COVID-19 vaccines tells us
|
Loubet, Paul
|
|
|
22 |
8 |
p. 1092-1093
|
artikel
|
| 53 |
WHO's first global infection prevention and control report
|
Balakrishnan, Vijay Shankar
|
|
|
22 |
8 |
p. 1122
|
artikel
|
Tijdschrift beschrijving